Venus Medtech (Hangzhou) Inc.

SEHK:2500 Stock Report

Market Cap: HK$2.5b

Venus Medtech (Hangzhou) Management

Management criteria checks 1/4

Venus Medtech (Hangzhou)'s CEO is Lin Haosheng Lim, appointed in Dec 2016, has a tenure of 7.17 years. total yearly compensation is CN¥1.26M, comprised of 85.4% salary and 14.6% bonuses, including company stock and options. directly owns 0.72% of the company’s shares, worth HK$17.67M. The average tenure of the management team and the board of directors is 1.9 years and 2.9 years respectively.

Key information

Lin Haosheng Lim

Chief executive officer

CN¥1.3m

Total compensation

CEO salary percentage85.4%
CEO tenure7.2yrs
CEO ownership0.7%
Management average tenure1.9yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

Oct 05
Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

May 29
Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

May 11
What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Apr 07
Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Oct 12
Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Sep 04
Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Jul 28
We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Mar 29
Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Jan 09
Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

Dec 01
Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

Aug 16
We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Jul 12
A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Apr 26
Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Apr 05
Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

Mar 07
Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Feb 14
What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Jan 19
Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Dec 29
Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Dec 29
Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Dec 08
Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

CEO Compensation Analysis

How has Lin Haosheng Lim's remuneration changed compared to Venus Medtech (Hangzhou)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-CN¥1b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥1mCN¥1m

-CN¥1b

Sep 30 2022n/an/a

-CN¥759m

Jun 30 2022n/an/a

-CN¥461m

Mar 31 2022n/an/a

-CN¥417m

Dec 31 2021CN¥1mCN¥694k

-CN¥374m

Compensation vs Market: Lin Haosheng's total compensation ($USD175.50K) is below average for companies of similar size in the Hong Kong market ($USD398.47K).

Compensation vs Earnings: Lin Haosheng's compensation has increased whilst the company is unprofitable.


CEO

Lin Haosheng Lim (49 yo)

7.2yrs

Tenure

CN¥1,263,000

Compensation

Mr. Hou-Sen Lim, also known as Lin Haosheng, MEng. Co-founded Transcatheter Technologies GmbH in 2009 and serves as its Managing Director and Chief Technology Officer. He serves as Chief Operating Officer...


Leadership Team

NamePositionTenureCompensationOwnership
Hou-Sen Lim
GM, COO & CTO7.2yrsCN¥1.26m0.72%
CN¥ 17.7m
Fei Wang
Chief Financial Officerless than a yearno datano data
Joyce Heo
Director of Sales1.9yrsno datano data
Christopher Richardson
Head of U.S. Operations4.6yrsno datano data
Amir Gross
Head of Venus Global Heart Valve Innovation Center1.9yrsno datano data
Shakeel Osman
Senior Vice President of Sales Europe1.9yrsno datano data
Liu Meirong
Executive Director1.1yrsno datano data
Liqiao Ma
Executive Directorless than a yearno data0.0084%
CN¥ 208.0k
Wai Chiu Wong
Company Secretary3.1yrsno datano data

1.9yrs

Average Tenure

49yo

Average Age

Experienced Management: 2500's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Liu Meirong
Executive Director1.1yrsno datano data
Liqiao Ma
Executive Directorless than a yearno data0.0084%
CN¥ 208.0k
Martin B. Leon
Member of Advisory Boardno datano datano data
Chaim Lotan
Member of Global Advisory Board4.1yrsno datano data
Ting Yuk Wu
Independent Non-Executive Director5.3yrsCN¥423.00kno data
Chi Wai Suen
Independent Non-Executive Director4.6yrsCN¥335.00kno data
Wei Wang
Shareholders Representative Supervisor5.3yrsno datano data
Scott Lim
Member of Global Advisory Board4.1yrsno datano data
Min Shao
Employee Representative Supervisor1.5yrsno datano data
Zhang Ao
Non-Executive Director1.1yrsno datano data
Yue Li
Shareholders Representative Supervisor1.8yrsno datano data

2.9yrs

Average Tenure

48yo

Average Age

Experienced Board: 2500's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.